Contract Research Organization WCCT Global Announces Specialized Clinical Trial Program for Orphan Drug Development - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Contract Research Organization WCCT Global Announces Specialized Clinical Trial Program for Orphan Drug Development Full Service CRO WCCT Global announces program for orphan drug development.


Contract Research Organization WCCT Global Announces Specialized Clinical Trial Program for Orphan Drug Development

Full Service CRO WCCT Global announces program for orphan drug development.

PR Newswire

COSTA MESA, Calif., Feb. 19, 2014 /PRNewswire-iReach/ -- WCCT Global, a multi-site full service CRO that is headquartered in Southern California announced today a specialized program to conduct clinical research for sponsors who are engaged in orphan drug development.  Aside from the often referenced technical and commercial hurtles which must be overcome before deciding to launch the development program for an orphan indication, the necessity to attain adequate patient recruitment for the safety and efficacy trials in support of the intended orphan indication undoubtedly offers an equal or  greater challenge to the innovating sponsor.  Fortunately, WCCT Global's recently announced,  proprietary, "In-Site" patient recruitment method which utilizes multiple levels of advanced digital technologies designed to work, in concert, to facilitate successful patient recruitment is an excellent solution.  This cutting edge patient recruitment tool that focuses on identification of desired patients based on the utilization of multiple proprietary patient databases is ideally suited for identification of these sparsely populated patient groups. Therefore, WCCT Global is now able assist sponsors interested in the development of drugs for orphan indications, not only locate patient groups, but actually determine the best sites to conduct the clinical trial, thus, making the orphan disease recruitment process much more efficient for the study site and ultimately, the sponsor of the trial. Furthermore, "In-Site" is an advanced digital advertising process where WCCT Global can create an in-depth psychographic based on the orphan indication and apply specific targeting methods across digital and social media outlets in order to ensure ideally targeted patient access. WCCT Global's Chief Operating Officer Jon Rojas stated,

(Photo: http://photos.prnewswire.com/prnh/20140219/MN66627)

"We have established our specialized recruitment method which is uniquely applicable to the recruitment issues faced by sponsors that are developing orphan drugs.  We point this out because we feel there is a need in the clinical research industry that must to be filled. Our, "In-Site",  proprietary recruitment tool can play a vital role leading to the successful recruitment of clinical trials in support of Orphan Drug development programs for those sponsors  who choose partner with WCCT Global."

More information about WCCT Global:

 WCCT Global is a multi-site, full-service global contract research organization (CRO) of outsourced early drug development and late phase services to the pharmaceutical, biotechnology and medical device industries. The WCCT Global vision, "With compassion for people, we strive for tomorrow's therapies to be available today" truly exemplifies the focus and reason for our cutting-edge work both in our clinics and throughout our operations. As a drug development partner, WCCT Global collaborates with domestic and foreign innovator companies who need regulatory, program management, data management and strategic consulting support, with an emphasis on overseeing and executing trials in special disease populations, pediatric populations, ethno-bridging, and cardiac safety. WCCT has extensive experience with healthy volunteer studies including First-in-Human (FIH), as well as specific therapeutic expertise in Allergy, Asthma, HCV, Ophthalmology, Oncology, Renal, and Vaccines.

If you would like to request a discussion about WCCT Global capabilites, CLICK HERE 

Media Contact: Matt Miller, WCCT Global, 714.668.1500 ext.2029, Matt.Miller@wcct.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE WCCT Global

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
88%
Borrow lightly from EMA's pathway program?
4%
Create entirely its own pathway program?
8%
View Results
Untitled Document

Click here